Your browser doesn't support javascript.
loading
Comprehensive Analysis of Barrett's Esophagus: Focused on Carcinogenic Potential for Barrett's Cancer in Japanese Patients.
Ishikawa, Kentaro; Okimoto, Kenichiro; Matsumura, Tomoaki; Hirotsu, Yosuke; Amemiya, Kenji; Kishimoto, Takashi; Akizue, Naoki; Ohta, Yuki; Saito, Keiko; Maruoka, Daisuke; Nishimura, Motoi; Matsushita, Kazuyuki; Mochizuki, Hitoshi; Arai, Makoto; Kato, Jun; Yokosuka, Osamu; Omata, Masao; Kato, Naoya.
Afiliação
  • Ishikawa K; Department of Gastroenterology, Graduate School of Medicine, Chiba University Hospital, Inohana 1-8-1, Chiba-City, 260-8670, Japan.
  • Okimoto K; Department of Gastroenterology, Graduate School of Medicine, Chiba University Hospital, Inohana 1-8-1, Chiba-City, 260-8670, Japan. okimoto-k@chiba-u.jp.
  • Matsumura T; Department of Medical Oncology, Chiba University Hospital, Chiba, Japan. okimoto-k@chiba-u.jp.
  • Hirotsu Y; Department of Gastroenterology, Graduate School of Medicine, Chiba University Hospital, Inohana 1-8-1, Chiba-City, 260-8670, Japan.
  • Amemiya K; Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, Japan.
  • Kishimoto T; Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, Japan.
  • Akizue N; Department of Molecular Pathology, Graduate School of Medicine, Chiba University Hospital, Chiba, Japan.
  • Ohta Y; Department of Gastroenterology, Graduate School of Medicine, Chiba University Hospital, Inohana 1-8-1, Chiba-City, 260-8670, Japan.
  • Saito K; Department of Gastroenterology, Graduate School of Medicine, Chiba University Hospital, Inohana 1-8-1, Chiba-City, 260-8670, Japan.
  • Maruoka D; Department of Gastroenterology, Graduate School of Medicine, Chiba University Hospital, Inohana 1-8-1, Chiba-City, 260-8670, Japan.
  • Nishimura M; Department of Gastroenterology, Graduate School of Medicine, Chiba University Hospital, Inohana 1-8-1, Chiba-City, 260-8670, Japan.
  • Matsushita K; Clinical Research Center, Chiba University Hospital, Chiba, Japan.
  • Mochizuki H; Division of Laboratory Medicine, Chiba University Hospital, Chiba, Japan.
  • Arai M; Division of Laboratory Medicine, Chiba University Hospital, Chiba, Japan.
  • Kato J; Genome Analysis Center, Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, Japan.
  • Yokosuka O; Department of Gastroenterology, Graduate School of Medicine, Chiba University Hospital, Inohana 1-8-1, Chiba-City, 260-8670, Japan.
  • Omata M; Department of Medical Oncology, Chiba University Hospital, Chiba, Japan.
  • Kato N; Department of Gastroenterology, Graduate School of Medicine, Chiba University Hospital, Inohana 1-8-1, Chiba-City, 260-8670, Japan.
Dig Dis Sci ; 66(8): 2674-2681, 2021 08.
Article em En | MEDLINE | ID: mdl-32840705
ABSTRACT
BACKGROUND/

AIM:

Barrett's esophagus (BE) is a precursor of esophageal adenocarcinoma (EAC). Therefore, an accurate diagnosis of BE is important for the subsequent follow-up and early detection of EAC. However, the definitions of BE have not been standardized worldwide; columnar-lined epithelium (CLE) without intestinal metaplasia (IM) and/or < 1 cm is not diagnosed as BE in most countries. This study aimed to clarify the malignant potential of CLE without IM and/or < 1 cm genetically.

METHOD:

A total of 96 consecutive patients (including nine patients with EAC) who had CLE were examined. Biopsies for CLE were conducted, and patients were divided into those with IM and > 1 cm (Group A) and those without IM and/or < 1 cm (Group B). Malignant potential was assessed using immunochemical staining for p53. Moreover, causative genes were examined using next-generation sequencing (NGS) on ten patients without Helicobacter pylori infection and without atrophic gastritis.

RESULT:

Of the 96 patients, 66 were in Group B. The proportion of carcinoma/dysplasia in Group A was significantly higher than that in Group B (26.7% in Group A and 1.5% in Group B; p < 0.01). However, one EAC patient was found in Group B. In the immunostaining study for non-EAC patients, an abnormal expression of p53 was not observed in Group A, whereas p53 loss was observed in three patients (4.6%) in Group B. In the NGS study, a TP53 mutation was found in Group B.

CONCLUSION:

CLE without IM and/or < 1 cm has malignant potential. This result suggests that patients with CLE as well as BE need follow-up.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esôfago de Barrett / Neoplasias Esofágicas / Epitélio Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies / Screening_studies Limite: Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esôfago de Barrett / Neoplasias Esofágicas / Epitélio Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies / Screening_studies Limite: Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article